Skip to main content
OpenTrials
Completed

NCT Number: NCT06099028

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

This is a retrospective, researcher-initiated, database-based study that will retrospectively observe the treatment and medication patterns of about 22,500 patients with heart failure from 25 heart failure centers and 25 non-heart failure centers in the database of heart failure center. The proportion of patients with heart failure treatment drugs reaching the target dose recommended in the guidelines and discontinuation rate will be observed at 1 month, 3 months and 12 months follow up time point. The purpose of this study is to illustrate the current HF treatment status in HF center hospitals and non-HF center hospitals, which may provide insights for improving the clinical practice of heart failure treatment in China, and promote the standardization of heart failure treatment in China.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Cardiology, Peking University First Hospital

Beijing, 100034, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • An index HF diagnosis date in the records
  • Age ≥ 18 years old at initial diagnosis date
  • HF patients baseline characteristic record

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

  1. Number of GDMT drugs (classified as RAASi (including ARNI), beta blockers, MRA and SGLT2i)

    Time frame: At baseline and at 1 month, 3 month, 12 month follow-up time point

    Numbers of GDMT drugs of HF patients stratified by HF ejection fraction and by HF Center and Non-HF Center

  2. Use rates of GDMT drugs

    Time frame: At baseline and at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients using each GDMT drug，stratified by HF ejection fraction and by HF Center and Non-HF Center

Secondary outcomes

  1. The proportion of patients using 2 types of GDMT drugs

    Time frame: At baseline and at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients using 2 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center

  2. The proportion of patients using 3 types of GDMT drugs

    Time frame: At baseline and at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients using 3 of any 4 GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center

  3. The proportion of patients using 4 types of GDMT drugs

    Time frame: At baseline and at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients using all types of GDMT drugs，stratified by HF ejection fraction and by HF Center and Non-HF Center

  4. The proportion of patients with each GDMT drug in the target dose

    Time frame: at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients who achieved the target dose of each GDMT drug, stratified by HF ejection fraction and by HF Center and Non-HF Center

  5. Discontinuation rate of each GDMT drug

    Time frame: at 1 month, 3 month, 12 month follow-up time point

    The percentage of patients who discontinued GDMT drugs, stratified by HF ejection fraction and by HF Center and Non-HF Center

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Collaborators

  • AstraZeneca
  • China Cardiovascular Association

Registry information

Official study title

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China: a Retrospective Database-based Study

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Oct 25, 2023
Registry last updated
Jan 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.